医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NuGEN Announces 2014 Genomics Grant Challenge

2014年06月18日 PM09:00
このエントリーをはてなブックマークに追加


 

SAN CARLOS, Calif.

NuGEN Technologies, Inc., a market leader in the development of innovative sample preparation solutions for Next Generation Sequencing (NGS) applications, has announced the NuGEN 2014 Genomics Grant Challenge.

This is the fourth year that NuGEN has funded a $10,000 grant challenge. “This program has been well-received by the scientific community year after year, and we expect the grant challenge for target enrichment-focused studies to draw strong participation this year,” commented Doug Amorese, VP of R&D for NuGEN. “We look forward to receiving the study proposals and to catalyzing research efforts that may be stalled due to lack of funding. We were impressed by the high caliber of study designs received last year.”

“There are many promising research projects that don’t receive NIH grants, as funding has been more difficult to secure in recent years,” stated Elizabeth Hutt, CEO of NuGEN. “We are pleased to play a role in supporting biomedical research again this year with the Genomics Grant Challenge. Enabling genomic research projects to move forward not only advances discovery, but benefits the broader community. Through this initiative we are able to demonstrate our on-going commitment to life science.”

NuGEN is accepting non-confidential study proposals until July 31, 2014. All abstract submission will be reviewed and the winning proposal will be selected by a scientific committee, with the winner being notified on August 28, 2014. The 2014 Genomics Grant Challenge Award recipient will receive up to $10,000 of Ovation® Target Enrichment System reagents for targeted sequencing studies.

About NuGEN

NuGEN Technologies is a San Carlos, CA company focused on innovative sample preparation solutions for RNA and DNA that enable life scientists to do more with less. With reagent solutions that are quick, easy to use, and amenable to automation, NuGEN empowers researchers to prepare genomic samples of any size, from almost any source, regardless of the intended application or technology platform. For more information please visit www.nugen.com.

NuGEN and Ovation are registered trademarks of NuGEN Technologies, Inc.

CONTACT

NuGEN Technologies, Inc.
Carol Short, 650-590-3002
media@nugeninc.com

同じカテゴリーの記事 

  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続
  • ReNAgade Therapeutics继续致力于GanNA Bio和糖生物学的研究